Byoung Soo Kwon
Seoul National University · 医学
研究室紹介
Professor Byoung Soo Kwon's research lab specializes in interstitial lung diseases (ILDs), with a focus on fibrosing phenotypes, idiopathic pulmonary fibrosis (IPF), and the clinical implications of drug-induced and infection-related lung disorders. The lab investigates diagnostic criteria, prognostic markers, and treatment outcomes using real-world clinical data, particularly emphasizing high-resolution computed tomography (HRCT) patterns, tumor markers in ILD, and the management of complications such as leptomeningeal carcinomatosis in lung cancer patients. Their work bridges clinical radiology, pulmonary medicine, and oncology, aiming to improve patient stratification and therapeutic decision-making.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Abstract Background The progressive fibrosing (PF) phenotype of interstitial lung disease (ILD) is characterised by worsening respiratory symptoms, lung function, and extent of fibrosis on high-resolution computed tomography. We aimed to investigate the prevalence and clinical outcomes of PF-ILD in a real-world cohort and assess the prognostic significance of the PF-ILD diagnostic criteria. Methods Clinical data of patients with fibrosing ILD other than idiopathic pulmonary fibrosis (IPF) consec
PZA was the most common drug associated with SAEs among the first-line anti-TB drugs, and old age was an independent factor for SAE occurrence. This study suggests that the early recognition of whether the causative agent is PZA may improve effective treatment compliance, particularly in elderly patients.
Although it is known that the in vitro MICs of rifampin and ethambutol are poorly correlated with the clinical response in Mycobacterium avium complex (MAC) lung disease (MAC-LD), evidence for this is limited. This study investigated the association between treatment outcome and the in vitro MICs of rifampin and ethambutol in patients with MAC-LD.
BACKGROUND: A new clinical guideline for idiopathic pulmonary fibrosis (IPF) uses high-resolution computed tomography (HRCT) patterns for diagnostic purposes. However, it is unknown how they relate to the IPF clinical course. We aimed to investigate whether HRCT patterns could be used to predict lung function changes and survival in patients with IPF. METHODS: Clinical data were retrospectively reviewed in 337 patients with IPF (all biopsy-proven cases). HRCT patterns were classified according t
The clinical implication of using serum tumor markers in patients with interstitial lung disease (ILD) is inconclusive. In this retrospective study, we analyzed the data of 1176 subjects (294 with ILDs and 882 healthy controls). Eligible patients were who had at least one or more available tumor marker results [carbohydrate antigen (CA) 19-9, CA 125, and carcinoembryonic antigen (CEA)] with no evidence of malignancies or other benign diseases that could be related to the increasing concentration
BACKGROUND: We investigated the risk factors for leptomeningeal carcinomatosis (LMC) and compared clinical efficacies of various treatment modalities including intrathecal (IT) chemotherapy in patients with lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations. METHODS: Using clinical research data from the Asan Medical Center, we retrospectively analyzed data of patients diagnosed with LMC, confirmed via cerebrospinal fluid (CSF) analysis from January 2008 to December
There have been limited studies on the association between prognosis and body weight change in patients with idiopathic pulmonary fibrosis (IPF). This single-center retrospective observational study evaluated the impact of weight loss on outcomes in Korean patients with IPF receiving pirfenidone at a tertiary medical institution. We analyzed 215 IPF patients prescribed pirfenidone from January 1st, 2015 to December 31st, 2019. The patients were categorized into maintained weight (MW; weight gain
<b>Approximately 60% of patients who are successfully treated for their first recurrence of MAC lung disease eventually experience a second recurrence. Approximately half of the second recurrence patients require anti-MAC treatment.</b>http://ow.ly/3G2R30meImC
Pulmonary artery sarcoma (PAS) is a rare but lethal malignant neoplasm that often mimics pulmonary artery embolism. However, owing to its rarity as well as fatality, there has been no firm consensus with regard to the standard diagnostic tool. We evaluate the feasibility of endovascular catheter biopsy as a diagnostic modality for PAS. We retrospectively reviewed the medical records of patients with histologically confirmed PAS between 2000 and 2016 at Asan Medical Center. Among a total of 25 pa
In patients with acquired resistance to initial EGFR-TKI therapy, switched EGFR-TKI retreatment may be a salvage therapy for individuals possessing positive retreatment response predictors.
Hypersensitivity pneumonitis (HP) is characterized as an immune-mediated interstitial lung disease with heterogeneous clinical manifestations and presents complex diagnostic challenges. This clinical guideline provides a comprehensive framework for diagnosing and managing HP, accentuating the evolving classification into fibrotic and nonfibrotic subtypes. By integrating current clinical guidelines and expert consensus, it addresses essential aspects such as radiologic and histopathologic finding
Background: This study aimed to estimate therapeutic effects of first-generation epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) in real-world practice, by analyzing survival outcomes in an unselected, Korean female population with advanced lung cancer based on the National Health Insurance Service database. Methods: We identified women with newly diagnosed advanced lung cancer from January 2004 to December 2013. For progression-free survival (PFS) and overall survival (O
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterized by worsening lung function and dyspnea. The prognosis of IPF patients is poor, as median survival is approximately 3 years. However, recently developed IPF-specific therapies have shown improved efficacies in terms of reducing lung function decline and mortality. Therefore, the early recognition and accurate diagnosis of IPF are crucial. In 2018, new guidelines for the diagnosis of IPF were pub
Research Areas
Byoung Soo Kwonの研究をNubintでさらに深く
この研究室の論文をアプリで開き、AIと共に読み、要約し、引用しましょう。